|
|
Blood, 15 November 2003, Vol. 102, No. 10, pp. 3837-3844.
Prepublished online as a Blood First Edition Paper on July 24, 2003; DOI 10.1182/blood-2003-04-1193.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Farida Djouad,
Pascale Plence,
Claire Bony,
Philippe Tropel,
Florence Apparailly,
Jacques Sany,
Danièle Noël, and
Christian Jorgensen
From INSERM U475, Montpellier, France; INSERM U318, Hôpital de La Tronche, La Tronche, France; and Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France.
Mesenchymal stem cells (MSCs) are largely studied for their potential clinical use. Recently, they have gained further interest after demonstration of an immunosuppressive role. In this study, we investigated whether in vivo injection of MSCs could display side effects related to systemic immunosuppression favoring tumor growth. We first showed in vitro that the murine C3H10T1/2 (C3) MSC line and primary MSCs exhibit immunosuppressive properties in mixed lymphocyte reaction. We demonstrated that this effect is mediated by soluble factors, secreted only on  activation of MSCs in the presence of splenocytes. Moreover, the immunosuppression is mediated by CD8+ regulatory cells responsible for the inhibition of allogeneic lymphocyte proliferation. We then demonstrated that the C3 MSCs expressing the human bone morphogenetic protein 2 (hBMP-2) differentiation factor were not rejected when implanted in various allogeneic immunocompetent mice and were still able to differentiate into bone. Importantly, using a murine melanoma tumor model, we showed that the subcutaneous injection of B16 melanoma cells led to tumor growth in allogeneic recipients only when MSCs were coinjected. Although the potential side effects of immunosuppression induced by MSCs have to be considered in further clinical studies, the usefulness of MSCs for various therapeutic applications still remains of great interest. (Blood. 2003;102:3837-3844)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Atoui, D. Shum-Tim, and R. C.J. Chiu
Myocardial regenerative therapy: immunologic basis for the potential "universal donor cells".
Ann. Thorac. Surg.,
July 1, 2008;
86(1):
327 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Parekkadan, A. W. Tilles, and M. L. Yarmush
Bone Marrow-Derived Mesenchymal Stem Cells Ameliorate Autoimmune Enteropathy Independently of Regulatory T Cells
Stem Cells,
July 1, 2008;
26(7):
1913 - 1919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lazennec and C. Jorgensen
Concise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit?
Stem Cells,
June 1, 2008;
26(6):
1387 - 1394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-P. Li, S. Paczesny, E. Lauret, S. Poirault, P. Bordigoni, F. Mekhloufi, O. Hequet, Y. Bertrand, J.-P. Ou-Yang, J.-F. Stoltz, et al.
Human Mesenchymal Stem Cells License Adult CD34+ Hemopoietic Progenitor Cells to Differentiate into Regulatory Dendritic Cells through Activation of the Notch Pathway
J. Immunol.,
February 1, 2008;
180(3):
1598 - 1608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Magatti, S. De Munari, E. Vertua, L. Gibelli, G. S. Wengler, and O. Parolini
Human Amnion Mesenchyme Harbors Cells with Allogeneic T-Cell Suppression and Stimulation Capabilities
Stem Cells,
January 1, 2008;
26(1):
182 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Nauta and W. E. Fibbe
Immunomodulatory properties of mesenchymal stromal cells
Blood,
November 15, 2007;
110(10):
3499 - 3506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chabannes, M. Hill, E. Merieau, J. Rossignol, R. Brion, J. P. Soulillou, I. Anegon, and M. C. Cuturi
A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells
Blood,
November 15, 2007;
110(10):
3691 - 3694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Rasmusson, M. Uhlin, K. Le Blanc, and V. Levitsky
Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes
J. Leukoc. Biol.,
October 1, 2007;
82(4):
887 - 893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Romieu-Mourez, M. Francois, M.-N. Boivin, J. Stagg, and J. Galipeau
Regulation of MHC Class II Expression and Antigen Processing in Murine and Human Mesenchymal Stromal Cells by IFN-{gamma}, TGF-beta, and Cell Density
J. Immunol.,
August 1, 2007;
179(3):
1549 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Haniffa, X.-N. Wang, U. Holtick, M. Rae, J. D. Isaacs, A. M. Dickinson, C. M. U. Hilkens, and M. P. Collin
Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells
J. Immunol.,
August 1, 2007;
179(3):
1595 - 1604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Li, N. Ma, L.-L. Ong, C. Nesselmann, C. Klopsch, Y. Ladilov, D. Furlani, C. Piechaczek, J. M. Moebius, K. Lutzow, et al.
Bcl-2 Engineered MSCs Inhibited Apoptosis and Improved Heart Function
Stem Cells,
August 1, 2007;
25(8):
2118 - 2127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Djouad, L.-M. Charbonnier, C. Bouffi, P. Louis-Plence, C. Bony, F. Apparailly, C. Cantos, C. Jorgensen, and D. Noel
Mesenchymal Stem Cells Inhibit the Differentiation of Dendritic Cells Through an Interleukin-6-Dependent Mechanism
Stem Cells,
August 1, 2007;
25(8):
2025 - 2032.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Prevosto, M. Zancolli, P. Canevali, M. R. Zocchi, and A. Poggi
Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction
Haematologica,
July 1, 2007;
92(7):
881 - 888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Prockop and S. D. Olson
Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions
Blood,
April 15, 2007;
109(8):
3147 - 3151.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Sun, H. Zhang, X. Feng, Y. Hou, L. Lu, and L. Fan
Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus
Lupus,
February 1, 2007;
16(2):
121 - 128.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Tolar, A. J. Nauta, M. J. Osborn, A. Panoskaltsis Mortari, R. T. McElmurry, S. Bell, L. Xia, N. Zhou, M. Riddle, T. M. Schroeder, et al.
Sarcoma Derived from Cultured Mesenchymal Stem Cells
Stem Cells,
February 1, 2007;
25(2):
371 - 379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Sato, K. Ozaki, I. Oh, A. Meguro, K. Hatanaka, T. Nagai, K. Muroi, and K. Ozawa
Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells
Blood,
January 1, 2007;
109(1):
228 - 234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-J. Chang, M.-L. Yen, Y.-C. Chen, C.-C. Chien, H.-I. Huang, C.-H. Bai, and B. L. Yen
Placenta-Derived Multipotent Cells Exhibit Immunosuppressive Properties That Are Enhanced in the Presence of Interferon-{gamma}
Stem Cells,
November 1, 2006;
24(11):
2466 - 2477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Yanez, M. L. Lamana, J. Garcia-Castro, I. Colmenero, M. Ramirez, and J. A. Bueren
Adipose Tissue-Derived Mesenchymal Stem Cells Have In Vivo Immunosuppressive Properties Applicable for the Control of the Graft-Versus-Host Disease
Stem Cells,
November 1, 2006;
24(11):
2582 - 2591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Nauta, G. Westerhuis, A. B. Kruisselbrink, E. G. A. Lurvink, R. Willemze, and W. E. Fibbe
Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting
Blood,
September 15, 2006;
108(6):
2114 - 2120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze, and W. E. Fibbe
Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34+-Derived and Monocyte-Derived Dendritic Cells
J. Immunol.,
August 15, 2006;
177(4):
2080 - 2087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sudres, F. Norol, A. Trenado, S. Gregoire, F. Charlotte, B. Levacher, J.-J. Lataillade, P. Bourin, X. Holy, J.-P. Vernant, et al.
Bone Marrow Mesenchymal Stem Cells Suppress Lymphocyte Proliferation In Vitro but Fail to Prevent Graft-versus-Host Disease in Mice.
J. Immunol.,
June 15, 2006;
176(12):
7761 - 7767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Dunbar, M. I. Sandstrom, J. Rossignol, and L. Lescaudron
Neurotrophic Enhancers as Therapy for Behavioral Deficits in Rodent Models of Huntington's Disease: Use of Gangliosides, Substituted Pyrimidines, and Mesenchymal Stem Cells.
Behav Cogn Neurosci Rev,
June 1, 2006;
5(2):
63 - 79.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Y. Khakoo, S. Pati, S. A. Anderson, W. Reid, M. F. Elshal, I. I. Rovira, A. T. Nguyen, D. Malide, C. A. Combs, G. Hall, et al.
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma
J. Exp. Med.,
May 15, 2006;
203(5):
1235 - 1247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Stagg, S. Pommey, N. Eliopoulos, and J. Galipeau
Interferon-{gamma}-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell
Blood,
March 15, 2006;
107(6):
2570 - 2577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari, and L. Moretta
Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation
Blood,
February 15, 2006;
107(4):
1484 - 1490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Aluigi, M. Fogli, A. Curti, A. Isidori, E. Gruppioni, C. Chiodoni, M. P. Colombo, P. Versura, A. D'Errico-Grigioni, E. Ferri, et al.
Nucleofection Is an Efficient Nonviral Transfection Technique for Human Bone Marrow-Derived Mesenchymal Stem Cells
Stem Cells,
February 1, 2006;
24(2):
454 - 461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Sotiropoulou, S. A. Perez, M. Salagianni, C. N. Baxevanis, and M. Papamichail
Characterization of the Optimal Culture Conditions for Clinical Scale Production of Human Mesenchymal Stem Cells
Stem Cells,
February 1, 2006;
24(2):
462 - 471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Minguell and A. Erices
Mesenchymal Stem Cells and the Treatment of Cardiac Disease
Experimental Biology and Medicine,
January 1, 2006;
231(1):
39 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail
Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells
Stem Cells,
January 1, 2006;
24(1):
74 - 85.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Eliopoulos, J. Stagg, L. Lejeune, S. Pommey, and J. Galipeau
Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice
Blood,
December 15, 2005;
106(13):
4057 - 4065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Poggi, C. Prevosto, A.-M. Massaro, S. Negrini, S. Urbani, I. Pierri, R. Saccardi, M. Gobbi, and M. R. Zocchi
Interaction between Human NK Cells and Bone Marrow Stromal Cells Induces NK Cell Triggering: Role of NKp30 and NKG2D Receptors
J. Immunol.,
November 15, 2005;
175(10):
6352 - 6360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Rodriguez, D. Pisani, C. A. Dechesne, C. Turc-Carel, J.-Y. Kurzenne, B. Wdziekonski, A. Villageois, C. Bagnis, J.-P. Breittmayer, H. Groux, et al.
Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse
J. Exp. Med.,
May 2, 2005;
201(9):
1397 - 1405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Glennie, I. Soeiro, P. J. Dyson, E. W.-F. Lam, and F. Dazzi
Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells
Blood,
April 1, 2005;
105(7):
2821 - 2827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Beyth, Z. Borovsky, D. Mevorach, M. Liebergall, Z. Gazit, H. Aslan, E. Galun, and J. Rachmilewitz
Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness
Blood,
March 1, 2005;
105(5):
2214 - 2219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Heng, H. Liu, and T. Cao
Potential Benefits of Co-transplanting Autologous Adult Stem Cells Together with Human Embryonic Stem Cells or Their Differentiated Derivatives
Ann. Clin. Lab. Sci.,
January 1, 2005;
35(1):
3 - 6.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Meisel, A. Zibert, M. Laryea, U. Gobel, W. Daubener, and D. Dilloo
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation
Blood,
June 15, 2004;
103(12):
4619 - 4621.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
